There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptinyx Inc (APTX) and Amgen Inc (AMGN) with bullish sentiments.
Aptinyx Inc (APTX)
In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Aptinyx Inc, with a price target of $12. The company’s shares opened today at $3.85, close to its 52-week low of $3.45.
Duncan wrote:
“We reiterate our OW rating and 12-month PT of $12 on APTX. With an initial focus on large indications within chronic pain, there are multiple nervous system disorder opptys for the company’s candidates that have a better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models look promising, and important PoC trial data should emerge this year. Valuation Summary We use a discounted NPV revenue calculation that yields ~$10 for NYX-2925 in DPN and ~$2 for pipeline placeholder ($75M total NPV) in fibromyalgia.”
According to TipRanks.com, Duncan is a 4-star analyst with an average return of 7.6% and a 50.2% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Crinetics Pharmaceuticals Inc, and KalVista Pharmaceuticals Inc.
Currently, the analyst consensus on Aptinyx Inc is a Moderate Buy with an average price target of $13.50.
See today’s analyst top recommended stocks >>
Amgen Inc (AMGN)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Amgen Inc today and set a price target of $208. The company’s shares opened today at $179.32.
Syed said:
“We note there was a $20MM benefit in 4Q18 due to an accounting adjustment, which would have made 4Q18 sales $75MM, vs 1Q19 sales of $59MM.”
According to TipRanks.com, Syed is a 1-star analyst with an average return of -2.6% and a 40.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $217, a 21.0% upside from current levels. In a report issued on April 16, BMO Capital also maintained a Buy rating on the stock with a $229 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
